Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Tesla Raises Cybertruck Prices by $5,000 in US 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Trump Buys SpaceX Shares After Record IPO 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
(4) - EconoTimes)
Add as a preferred source on Google
SAN DIEGO, April 25, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported grants under its Amended and Restated 2017 Inducement Equity Incentive Plan to two new employees who joined Vital Therapies.
The grants made April 24, 2018 are awards of nonstatutory stock options to purchase up to a total of 32,526 shares of Vital Therapies common stock. The options have an exercise price of $5.50, the closing price of Vital Therapies’ common stock on the grant date. The option grants will vest over four years with 1/48th of the total shares vesting monthly, subject to continued service. Each stock option has a ten-year term and is subject to the terms and conditions of the Amended and Restated 2017 Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The grants were approved by the Vital Therapies Board of Directors on April 24, 2018. In accordance with NASDAQ Listing Rule 5635(c)(4), the grants were made as an inducement material to entering into an employment relationship with Vital Therapies.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
